Phase 2 Crohn's Disease and Colitis Trial, Recruiting (NCT07333716)

Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT07333716 Sponsor: Tanta University Condition: Crohn's Disease and Colitis

Printed from Voxsanity (voxsanity.com.au) — NCT07333716 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Crohns Disease And Colitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults of any gender between 18 and 65 years of age
People who have been diagnosed with active mild to moderate ulcerative colitis, based on guidelines from the American College of Gastroenterology
People who are currently being treated with a medication called mesalamine (also known as 5-aminosalicylic acid) for their condition

Who may not be able to join:

People with severe ulcerative colitis
People with significant problems with their liver or kidney function
People who are pregnant or currently breastfeeding
People currently using steroid medications, whether taken by mouth/injection or used rectally
People currently using immunosuppressant medications or biological therapies
People with a known allergy to desloratadine or any of its ingredients
People who have another inflammatory disease in addition to ulcerative colitis
People with a history of colon cancer
People who have had part or all of their colon surgically removed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Romisaa R Abd Alnapy, Tanta University

Phone: +201288667650

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07333716

Sponsor: Tanta University

Phase: Phase 2

Status: Recruiting

Condition: Crohn's Disease and Colitis

Trial contact: +201288667650

More information: https://clinicaltrials.gov/study/NCT07333716

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults of any gender between 18 and 65 years of age
People who have been diagnosed with active mild to moderate ulcerative colitis, based on guidelines from the American College of Gastroenterology
People who are currently being treated with a medication called mesalamine (also known as 5-aminosalicylic acid) for their condition

Who may not be able to join:

People with severe ulcerative colitis
People with significant problems with their liver or kidney function
People who are pregnant or currently breastfeeding
People currently using steroid medications, whether taken by mouth/injection or used rectally
People currently using immunosuppressant medications or biological therapies
People with a known allergy to desloratadine or any of its ingredients
People who have another inflammatory disease in addition to ulcerative colitis
People with a history of colon cancer
People who have had part or all of their colon surgically removed

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Tanta University

Registry

ClinicalTrials.gov

Start date

26 January 2026

Est. completion

1 February 2027

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in disease activity and severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov